Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 4/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3483229 | 0.69 | — | — | |
| SCHEMBL2067409 | 0.68 | SLC9A1 (0.36) | — | |
| SCHEMBL10151404 | 0.67 | ADORA2A (0.41) | ADORA2AADORA2BSPRPOLB | |
| SCHEMBL626956 | 0.67 | L3MBTL1 (0.54) | ADORA2AADORA2BSPRPOLBPDE10A | |
| SCHEMBL3482894 | 0.66 | DYRK1A (0.31) | — | |
| Ammonia Solution, Strong SCHEMBL23150476 | 0.65 | ADORA2A (0.39) | ADORA2AADORA2BSPRPOLB | |
| SCHEMBL3483035 | 0.65 | ADORA2A (0.48) | ADORA2AADORA2B | |
| SCHEMBL14430228 | 0.64 | SPR (0.52) | ADORA2AADORA2BSPRPOLBPDE10A | |
| SCHEMBL21054329 | 0.64 | LRRK2 (0.35) | — | |
| SCHEMBL24122196 | 0.64 | SPR (0.46) | ADORA2AADORA2BSPRPOLBPDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | claimed |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | US | claimed |
| US-20140066412-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-06 | — | — | US | claimed |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (US) | 2013-09-19 | — | — | US | claimed |
| US-8461159-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | Jannsen Pharmaceutica BV (BE) | 2013-06-11 | — | — | US | claimed |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-29 | — | — | US | claimed |
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-22 | — | — | US | claimed |
| EP-1358188-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2003-11-05 | — | — | EP | claimed |
| WO-2002060900-A2 | ANTAGONISTS OF MCP-1 FUNCTION AND METHODS OF USE THEREOF | TELIK, INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-9006225-B2 | Stable pharmaceutical composition | ASAHI KASEI PHARMA CORPORATION (JP) | 2015-04-14 | — | — | US | disclosed |
| US-8877769-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSEEN PHARMACEUTICA NV (BG) | 2014-11-04 | — | — | US | disclosed |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-08-07 | — | — | US | disclosed |
| US-20140066412-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2014-03-06 | — | — | US | disclosed |
| US-8598356-B2 | Heteroaryl-substituted urea modulators of fatty acid amide hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-03 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | ASAHI KASEI PHAMA CORPORATION (JP) | 2007-09-13 | — | — | US | disclosed |
| EP-1660427-A4 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORP (JP) | 2006-12-20 | — | — | EP | disclosed |
| EP-1660427-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2006-05-31 | — | — | EP | disclosed |
| EP-1595866-A1 | COMPOUND INHIBITING DIPEPTIDYL PEPTIDASE IV | Sanwa Kagaku Kenkyusho Co., Ltd. (JP) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005016862-A1 | SUBSTITUTED ARYLALKANOIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230490-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ADORA2A 484/4885ADORA2B 436/4885SPR 4176/4885 |
| US-20140221322-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ADORA2A 557/4885ADORA2B 523/4885SPR 4183/4885 |
| US-20140066412-A1 | HETEROARYL SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ADORA2A 557/4885ADORA2B 523/4885SPR 4183/4885 |
| US-20130245022-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ADORA2A 484/4885ADORA2B 436/4885SPR 4176/4885 |
| US-20110237596-A1 | HETEROARYL-SUBSTITUTED UREA MODULATORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, GPR119 | ADORA2A 484/4885ADORA2B 436/4885SPR 4176/4885 |
| US-20070213333-A1 | Substituted arylalkanoic acid derivatives and use thereof | CYSLTR1, CYSLTR2, LTB4R2 | ADORA2A 680/4885ADORA2B 345/4885SPR 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.